CEL-SCI reports recent data review by IDMC for its pivotal phase 3 cancer study
CEL-SCI announced the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. August 15, 2018